Need access to NeoLink? Contact your Sales rep or our Client Services team at 866.776.5907, Option 3
September 24, 2025
Molecular
MPN Testing – Effective October 13, 2025, the following changes will be implemented for the MPN-specific assays as outlined in the below table.
- Methodology: These tests will be performed by next-generation sequencing (NGS) instead of PCR and/or bi-directional sequencing.
- Test Name: The test names will be updated to reflect the new change in methodology and to better describe the scope of JAK2 testing.
- Benefits
- Better sensitivity
- More exon coverage on JAK2 gene
- Turnaround Time (TAT) will improve to 7 days or less for all tests
- CPT codes and pricing will remain the same.
- Interface Clients: This test update will involve a change in test names and codes. Please refer to the Interface Updates section for more info.
| Old Test Names | New Test Names |
|---|
| MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL | MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-15, CALR, and MPL |
| JAK2 V617F Mutation Analysis – Qualitative | JAK2 V617F Mutation Analysis by NGS |
| JAK2 Exon 12-13 Mutation Analysis | JAK2 Extended (Exon 12-15 non-V617F) Mutation Analysis by NGS |
| Calreticulin (CALR) Mutation Analysis | CALR Mutation Analysis by NGS |
| MPL Mutation Analysis | MPL Mutation Analysis by NGS |
Claudin18.2 in Gastric Cancer
CLDN18.2, a protein highly expressed in gastric cancer cells, is a valuable biomarker for diagnosis and treatment planning.
Detecting the presence of Claudin18.2 (CLDN18.2) can help patients with gastric or gastroesophageal junction adenocarcinoma determine eligibility for a first-line targeted therapy.
Belonging to the family of transmembrane proteins, Claudins reside throughout the body within the tight junctions formed between epithelial cells, regulating cellular structure and function.1 Impacted cellular function can promote oncogenesis and thus cancer progression, making Claudins an attractive biomarker for improving patient treatment outcomes.2,3,4
To learn more about CLDN18.2 testing, please visit our website.
- www.claudin182.com
- Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008;14(23):7624-34.
- Hong JY, An JY, Lee J, et al. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res. 2020;9(5):3367-3374. doi:10.21037/tcr-19-1876
- VENTANA CLDN18 (43-14A) RxDx Assay. Package insert. Roche; 2023.
IDHNow for AML Sponsored Testing Program
For AML patients, time is of the essence. Get IDHNow for AML for informed treatment decisions.
NeoGenomics has partnered with Servier to provide IDHNow for AML, a sponsored testing program for eligible AML patients. Participating patients benefit from expedited IDH1 profiling results, allowing you to make treatment decisions as quickly as possible for your patients. Patients with newly diagnosed AML who do not have a known IDH1 mutation, and who reside and receive treatment in the US and its territories may be eligible for the IDHNow for AML Sponsored Testing Program at no cost.
To learn more and order today, please visit our website.
For a complete list of recent test updates, click here for a downloadable document to view the impacted interface test codes.